sTable 1. Baseline characteristics of ICI treated metastatic cancer patients for which immunophenotyping was performed pre-ICI and after first ICI.

Features	Pre-ICI	After first ICI	P-value
Total	89	65	
Gender			0.1495
Male	65 (73.03%)	50 (76.92%)	
Female	24(26.97%)	15(23.08%)	
Age			0.1167
>=60	29(32.58%)	21(32.31%)	
<60	60(67.42%)	44(67.69%)	
Tumor entity			0.6233
HNSCC	40(44.94%)	29(44.62%)	
NSCLC	39(43.82%)	31(47.69%)	
others	10(11.24%)	5(7.69%)	
Brain metastases			0.05829
Yes	17(19.1%)	14(21.54%)	
No	72(80.9%)	51(78.46%)	
PD-L1 TPS			0.9467
<1%	31(34.83%)	23(35.38%)	
1-49%	28(31.46%)	20(30.77%)	
50%-100%	28(31.46%)	21(32.31%)	
NA	2(2.25%)	1(1.54%)	
Number of previous treatments			0.1317
0-1	32 (35.96%)	23(35.38%)	
≥2	57(64.04%)	42(64.62%)	